# Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas

> **NCT01490047** · PHASE1 · WITHDRAWN · sponsor: **Ludwig Institute for Cancer Research**

## Conditions studied

- Solid Tumors
- Lymphomas

## Interventions

- **DRUG:** Recombinant human TNF-α
- **DRUG:** Liposomal doxorubicin
- **DRUG:** Caelyx
- **DRUG:** Recombinant human TNF-α

## Key facts

- **NCT ID:** NCT01490047
- **Lead sponsor:** Ludwig Institute for Cancer Research
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-01
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2015-06-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01490047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01490047, "Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01490047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*